CD8A and melanoma: Combination treatment of advanced melanoma patients with ipilimumab and bevacizumab led to intense infiltration of the tumor vasculature with CD8+ T cells and CD163+ dendritic macrophages, increased E-selectin expression (indicating endothelial activation), and higher numbers of circulating memory CD4+ and CD8+ T cells (CCR7+/−CD45RO+) in the peripheral blood [34].